Browse the corpus

Ethambutol is a bacteriostatic drug that inhibits cell wall synthesis and is used to manage and treat tuberculosis (TB). The mechanism of action, dosing considerations, pharmacokinetics, adverse event profiles, contraindications, boxed warnings, and monitoring strategies are highlighted within a multi-drug treatment. In particular, the severe adverse drug reaction relating to optic neuropathy is discussed, with relevant interventions mentioned. New drugs like bedaquiline promise to improve TB outcomes, but addressing pharmacy challenges and ensuring interprofessional collaboration remains crucial for effective patient management with ethambutol therapy. Given the emergence of ethambutol-resistant TB strains, the emphasis on contraindicated single regimen use is important. This activity will highlight other key factors, such as off-label uses, dosing, and monitoring, pertinent to healthcare team members treating patients with tuberculosis and related conditions. The interprofessional team, including infectious disease specialists or ophthalmologists in complicated cases, is equipped with comprehensive knowledge to enhance patient care during therapy with ethambutol. Objectives: Identify the mechanism of action of ethambutol in comparison to other medications for tuberculosis. Evaluate the potential adverse effects of ethambutol with emphasis on optic neuropathy. Determine the appropriate monitoring for patients undergoing therapy with ethambutol. Strategize effective collaboration among interprofessional team members to improve treatment efficacy for patients who benefit from treatment with ethambutol. Access free multiple choice questions on this topic.

Signs and Symptoms of Toxicity One of the most well-known adverse effects is optic neuritis. The effect of neuritis is dose-related, with greater than 40% of adults developing toxicity at doses greater than 50 mg/kg and around 0% to 3% of adults developing toxicity at 15 mg/kg/daily.[21] Currently, unknown protocols detect subclinical ethambutol-induced ocular toxicity. The results of a study in Korea conducted various visual tests such as color vision tests, retinal nerve fiber layer optical coherence tomography tests, and pattern visual evoked potential tests. The results showed that retinal nerve fiber layer optical coherence tomography tests and pattern visual evoked potential tests were promising as they could detect changes in visual patterns after 6 months, while other tests in visual acuity, color vision, or visual fields showed no significant changes.[22] Management of Toxicity The manifestation of ethambutol-induced optic neuropathy appears to be from the chelation of copper. A study with 60 patients undergoing treatment with ethambutol monitored their serum copper levels. Statistical analysis confirmed a significant change in copper concentration, supporting the copper chelation effect.[23] An in-vitro study suggests that therapeutic copper can potentially prevent ethambutol-induced optic neuropathy while not compromising the bacteriostatic properties.[24] Patients who experience any visual symptoms should discontinue the drug immediately and consult their doctor.[25]

Ethambutol-induced optic neuropathy is a well-known disease that can be irreversible but is preventable. Timely and appropriate screenings are important in determining the outcome of the patient. According to epidemiologic studies investigating this neuropathy, between 0.7% and 1.29% of patients showed a prevalence of optic neuropathy when taking the World Health Organization recommended dosages. Optical coherence tomography demonstrated a clinically significant decrease in the thickness of the retinal nerve fiber layer.[26] Ethambutol-induced optic neuropathy is a well-known adverse effect of treatment; all patients on ethambutol should be screened regularly by ophthalmologists.[25] Although ethambutol is a bacteriostatic agent used to prevent the emergence of drug resistance to other first-line drugs, ethambutol-resistant strains are recognized. With the rise of drug-resistant strains of TB and the current 6-month regimen of 4 drugs that can potentially expand to 18 to 24 months, leading to inadequate compliance and poor outcomes, a search for different treatments persists. Completion of and compliance with the anti-tuberculosis regimen are paramount to treating TB patients and controlling TB globally.[27] The development of new drugs such as bedaquiline, pretomanid, delamanid, and bedaquiline to combat these challenges can significantly impact how tuberculosis is treated and transmitted.[5][28]

Ethambutol-induced optic neuropathy is a well-known disease that can be irreversible but is preventable. Timely and appropriate screenings are important in determining the outcome of the patient. According to epidemiologic studies investigating this neuropathy, between 0.7% and 1.29% of patients showed a prevalence of optic neuropathy when taking the World Health Organization recommended dosages. Optical coherence tomography demonstrated a clinically significant decrease in the thickness of the retinal nerve fiber layer.[26] Ethambutol-induced optic neuropathy is a well-known adverse effect of treatment; all patients on ethambutol should be screened regularly by ophthalmologists.[25] Although ethambutol is a bacteriostatic agent used to prevent the emergence of drug resistance to other first-line drugs, ethambutol-resistant strains are recognized. With the rise of drug-resistant strains of TB and the current 6-month regimen of 4 drugs that can potentially expand to 18 to 24 months, leading to inadequate compliance and poor outcomes, a search for different treatments persists. Completion of and compliance with the anti-tuberculosis regimen are paramount to treating TB patients and controlling TB globally.[27] The development of new drugs such as bedaquiline, pretomanid, delamanid, and bedaquiline to combat these challenges can significantly impact how tuberculosis is treated and transmitted.[5][28] Pharmacies are crucial in TB control, especially in high-burden countries. However, they often face challenges in providing quality care, including the availability of anti-TB drugs and patient management. Interventions, such as public-private mix initiatives, aim to improve case detection by training pharmacists to refer symptomatic patients for testing. Ethambutol, a key anti-TB drug, is often stocked, but quality assurance is essential. Future efforts should focus on expanding interventions to improve patient counseling and address inappropriate medication sales while establishing global pharmacy-specific guidelines and enhancing regulatory environments.[29] Given ethambutol's toxicity profile, the decision to treat tuberculosis cases should involve an interprofessional team, including infectious disease specialists. Close monitoring of the patient, careful assessment of the medication profile, and determining the susceptibility of the infection are all key factors in charting the therapeutic course. An interprofessional team approach and open communication between infectious disease specialists, nurse practitioners, physician assistants, pharmacists, and ophthalmologists are necessary to optimize patient outcomes with ethambutol therapy.